2Tsioufis C, Kordalis A, Flessas D,et al. Pathophysiology of resistant hypertension:the role of sympathetic nervous system[J]. Int J Hypertens,2011:642416.
3Barajas L, Liu L,Powers K. Anatomy of the renal innervation:intrarenal aspects and ganglia of origin[J]. Can J Physiol Pharmacol, 1992,70 (5) : 735-749.
4Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD[J]. J Am Soc Nephrol, 2012,23 (7): 1250-1257.
5Ubaid-Girioli S, Ferreira-Melo SE, Sonza LA, et al. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin Ⅱ receptor blocker combination therapy in patients with mild to moderate hypertension [J]. J Clin Hypertens (Greenwich), 2007,9 (10) : 770-774.
7Raji A, SeeIy EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients [J]. Diabetes Care, 2003,26( 1 ) : 172-178.
8Kraus D, Jager J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes[J]. Horm Meta Res, 2005,37 (7) :455-459.
10Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction:role of vascular superoxide anion formation and endothelial nitric oxide synthase expression[J]. J Am Coil Cardiol, 2002,39(2) :351-358.
10Hermida RC, Ayala DE, Cairo, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension [J]. J Hypertension, 2005, 46 (4): 1053.
